Navegando por Palavras-chave "gabapentine"

Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Síndrome das pernas inquietas: diagnóstico e tratamento. Opinião de especialistas brasileiros
    (Assoc Arquivos Neuro- Psiquiatria, 2007-09-01) Aloe, Flávio; Alves, Rosana S Cardoso; Andrade, Luiz Augusto Franco [UNIFESP]; Assis,Márcia; Bacelar, Andrea; Bezerra, Márcio; Cardoso, Francisco [UNIFESP]; Ferraz, Henrique Ballalai [UNIFESP]; Fonseca, Ronaldo Guimarães; Horta, Wagner; Haddad, Mônica Santoro; Hasan, Rosa; Mattos, James Pitágoras; Prado, Gilmar Fernandes do [UNIFESP]; Rizzo, Geraldo; Rodrigues, Nonato; Silva, Ademir Batista da [UNIFESP]; Silva, Delson Jose; Teive, Helio Afonso Ghizoni; Grupo Brasileiro de Estudos em Síndrome das Pernas Inquietas (GBE-SPI); Universidade de São Paulo (USP); Hosp Israelita Albert Einstein; Pratica privada; Practica Privada; Universidade Federal de Minas Gerais (UFMG); Universidade Federal de São Paulo (UNIFESP); UFCE; Universidade Federal de Goiás (UFG)
    This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized by abnormal sensations mostly but not exclusively in the legs which worsen in the evening and are improved by motion of the affected body part. its diagnosis is solely based on clinical findings. Therapeutic agents with efficacy supported by Class I studies are dopamine agonists, levodopa and gabapentine. Class 11 studies support the use of slow release valproic acid, clonazepan and oxycoclone. The GBE-SPI recommendations for management of SPI are sleep hygiene, withdrawal of medications capable of worsening the condition, treatment of comorbidities and pharmacological agents. The first choice agents are dopaminergic drugs, second choice are gabapentine or oxycodone, and the third choice are clonazepan or slow release valproic acid.